Literature DB >> 3764348

Incidence and prognosis of central nervous system infections in a birth cohort of 12,000 children.

P Rantakallio, M Leskinen, L von Wendt.   

Abstract

All types of central nervous system (CNS) infections were investigated in a 1966 birth cohort of 12,000 children from Northern Finland followed up from birth to the age of 14. 174 CNS infections occurred in 167 children, 110 boys and 64 girls. The annual incidence of bacterial CNS infections was 36.3/100,000 and that of viral infections 688.0/100 000. It is concluded that bacterial CNS infections were recorded very fully but only 2/3 of the viral infections could be traced, even though the more severe cases were quite well documented. 8/55 children (14.5%) with bacterial meningitis died; the corresponding figure for viral encephalitis and meningitis (excluding mumps) was 3/67 (4.5%). 17/55 (30.9%) developed mental retardation, epilepsy, cerebral palsy or hearing defect or some combination of these after bacterial CNS infection, and 9 (8.1%) after viral infection. The difference with respect to the children who had not experienced CNS infection was statistically significant only for the bacterial infection cases. CNS infections explained 7.6% of all deaths from 28 days to 14 years, 3% of the handicapping cases of cerebral palsy, mental retardation and epilepsy or some combination of these, and 6.6% of the hearing defects.

Entities:  

Mesh:

Year:  1986        PMID: 3764348     DOI: 10.3109/00365548609032339

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  15 in total

Review 1.  Viral meningitis.

Authors:  Sarah A E Logan; Eithne MacMahon
Journal:  BMJ       Date:  2008-01-05

Review 2.  Enteroviral meningitis. Cost of illness and considerations for the economic evaluation of potential therapies.

Authors:  T V Parasuraman; K Frenia; J Romero
Journal:  Pharmacoeconomics       Date:  2001-01       Impact factor: 4.981

3.  Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats.

Authors:  M A Galic; K Riazi; A K Henderson; S Tsutsui; Q J Pittman
Journal:  Neurobiol Dis       Date:  2009-08-04       Impact factor: 5.996

4.  Postnatal inflammation increases seizure susceptibility in adult rats.

Authors:  Michael A Galic; Kiarash Riazi; James G Heida; Abdeslam Mouihate; Neil M Fournier; Sarah J Spencer; Lisa E Kalynchuk; G Campbell Teskey; Quentin J Pittman
Journal:  J Neurosci       Date:  2008-07-02       Impact factor: 6.167

Review 5.  The choroid plexus-a multi-role player during infectious diseases of the CNS.

Authors:  Christian Schwerk; Tobias Tenenbaum; Kwang Sik Kim; Horst Schroten
Journal:  Front Cell Neurosci       Date:  2015-03-12       Impact factor: 5.505

6.  Neutralising Antibodies against Enterovirus and Parechovirus in IVIG Reflect General Circulation: A Tool for Sero-Surveillance.

Authors:  Karen Couderé; Karlijn van der Straten; Lieke Brouwer; Gerrit Koen; Hetty van Eijk; Dasja Pajkrt; Jean-Luc Murk; Katja C Wolthers
Journal:  Viruses       Date:  2021-05-29       Impact factor: 5.048

7.  Suboptimal management of central nervous system infections in children: a multi-centre retrospective study.

Authors:  Christine Kelly; Aman Sohal; Benedict D Michael; Andrew Riordan; Tom Solomon; Rachel Kneen
Journal:  BMC Pediatr       Date:  2012-09-07       Impact factor: 2.125

8.  Acute and recurrent viral meningitis.

Authors:  Larry E Davis
Journal:  Curr Treat Options Neurol       Date:  2008-05       Impact factor: 3.972

Review 9.  The incidence of acute encephalitis syndrome in Western industrialised and tropical countries.

Authors:  Fidan Jmor; Hedley C A Emsley; Marc Fischer; Tom Solomon; Penny Lewthwaite
Journal:  Virol J       Date:  2008-10-30       Impact factor: 4.099

Review 10.  Neuroinvasion and Inflammation in Viral Central Nervous System Infections.

Authors:  Tobias Dahm; Henriette Rudolph; Christian Schwerk; Horst Schroten; Tobias Tenenbaum
Journal:  Mediators Inflamm       Date:  2016-05-25       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.